MSF Access

15/10/2026

MSF welcomes the adoption of the UN Political declaration on pandemic prevention, preparedness and response this week which reinforces global solidarity and provides political momentum for ongoing negotiations on WHO-led Pandemic Agreement Annex on Pathogen Access and Benefit Sharing System (PABS).

MSF has been closely following the PABS negotiations since the start, actively sharing our position advocating for a strong, equitable and effective PABS system: https://msfaccess.org/pandemic-prevention-preparedness-and-response

24/09/2026

MSF published a technical brief analysing access challenges concerning three Bundibugyo Ebola Virus therapeutic candidates - MBP134, remdesivir, and obeldesivir. Publicly available information on pricing, licensing, supply, and post-trial access remains very limited despite repeated calls for transparency. Funders, researchers and policymakers engaged in therapeutics' clinical trials must act now to include the right access conditions in a transparent way.

Technical brief on Ebola therapeutics and key factors affecting access

01/09/2026

The current Ebola disease outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo has disproportionately affected children.

In a commentary published in The Lancet today, MSF calls for urgent action from all stakeholders involved in research on Bundibugyo virus treatment and prevention to ensure that children are meaningfully included in planned, evidence-generating research on medical countermeasures, and, in particular, have timely access to paediatric formulations for ongoing trials of oral post-exposure prophylaxis.

Children and pregnant women are known to be at high risk of death from Ebola virus disease.1,2 In the current outbreak of Bundibugyo virus in the Democratic Republic of the Congo, the inequality in outcomes is particularly stark for children. As of Aug 4, 2026, of 1124 deaths among people with confi...

21/08/2026

What is the global double standard in care? Authors from Voices in Action Diabetes outline the issue and explore possible solutions:

Newsletter Edition #374 [The Curated Primer] Subscribe Now! Readers, In today's edition, activists are calling for including insulin analogue pens as a first-line treatment option in the World Health Organization’s forthcoming guidelines for type 1 diabetes. Despite insulin being indispensable, th...

12/08/2026

🫁 Tuberculosis is one of the world's deadliest diseases. It is curable, but only half of all children with tuberculosis get diagnosed.

For Francisco, a child in Mozambique with drug-resistant tuberculosis, it took nine months, a period of malnutrition, and numerous trips to the hospital to get a diagnosis and begin treatment.

Francisco’s long road to diagnosis is common among children with TB, because laboratory tests are designed for adults — not for children.

Read our interview with a pediatrician on how tuberculosis treatment decision algorithms help diagnose children more effectively: https://msfaccess.org/how-tb-treatment-decision-algorithms-help-diagnose-children-paediatricians-experience?utm_source=facebook

05/08/2026

🤔 Testing, testing: what do you know about Ebola tests?

📩 ...and, take the opportunity to subscribe to our newsletter right before the August issue!

Ensuring sustainable, adapted, ready and available diagnostic capacity is critical for a quick response to disease outbreak, and in the current Ebola outbreak, this must be a priority.

30/07/2026

We are taking our demand directly to Gilead at the conference in Rio de Janeiro, Brazil - a country where people still can't access lenacapavir, even when they contributed to the clinical trials for this breakthrough drug.

Read more: www.instagram.com/p/DbThjxUH4gy/

29/07/2026

⬇️ Join our campaign. Tell Gilead to drop the price of lenacapavir and make it available to all.

The 26th International AIDS Society Conference starts today in Rio de Janeiro, Brazil. Gilead Sciences will be there presenting new research on lenacapavir, a twice-yearly HIV prevention injection that is nearly 100% effective.

Here's what they won't be talking about: Brazil, the country hosting this conference, still can't access lenacapavir for the people who need it. Communities in Brazil participated in the clinical trials that helped prove this drug works. Yet Gilead's pricing and supply decisions keep it out of reach in Brazil, as well as 25 other countries.

Gilead alone should not decide who gets lenacapavir and who doesn't.

Two shots. $40. Everywhere.
https://www.doctorswithoutborders.org/latest/campaigns/access-to-LEN

28/07/2026

It's and over a quarter of a million children are still acquiring chronic hepatitis B at birth each year, resulting in many premature deaths.

But this can be prevented👇

27/07/2026

Why is responding to an Ebola disease outbreak so challenging?
Beyond treating patients, responders must quickly diagnose cases, source essential supplies, and overcome logistical hurdles and often in resource-limited settings.

Join our Ebola disease webinar series: "Everything you need to know on diagnostics and supply, and why it's not easy."
📅 Tuesday, 28 July 2026
🕓 4:00 PM (KL/MNL) | 3:00 PM (BKK/JKT)

Speakers:
🔴 Sonjelle Shilton, Diagnostic Advisor, MSF Access
🔴 Antonio Martin, Head, Global Direct Procurement, MSF International
Moderator:
🔴Sinhye Ha, Regional Advisor for Asia Pacific, MSF Access

Have a question? Submit it when you register and we'll do our best to answer it live. Register now: https://tinyurl.com/3jcnhnve